26 completed, 16 recruiting, 13 unknown, 11 not yet recruiting. 39 Phase 2, 32 Phase 1, 9 Phase 3, 2 Not applicable.
Follow Keymed Biosciences Co.Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CM529D1 in Participants With Advanced Solid Tumors CM529D1 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 128 | 2026-11-27 | 2026-10-23 |
| Study of CM583 in Healthy Participants CM583, Placebo - Healthy | Phase 1 | Not yet recruiting | Keymed Biosciences Co.Ltd | 40 | 2026-10-01 | 2026-09-16 |
| CM336 for Active Sjogren's Syndrome Study CM336 - Primary Sjögren's Syndrome (pSS) | Phase 1 | Not yet recruiting | Keymed Biosciences Co.Ltd | 30 | 2026-06-01 | 2026-06-12 |
| A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） CM512 - Chronic Rhinosinusitis With Nasal Polyposis | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 120 | 2026-05-31 | 2026-06-30 |
| Study of CM383 in Healthy Subjects CM383 - Healthy | Phase 1 | Recruiting | Keymed Biosciences Co.Ltd | 30 | 2026-01-01 | 2026-01-23 |
| A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. CM512 - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 246 | 2025-12-01 | 2025-11-17 |
| Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) CM512 injection, placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 48 | 2025-11-27 | 2026-04-09 |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 158 | 2025-11-18 | 2025-12-17 |
| Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC Stapokibart and Finotonlimab - HNSCC | Phase 1 | Recruiting | Beijing Tongren Hospital | 10 | 2025-10-09 | 2026-05-04 |
| Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients CM336 Injection, Standard Of Care( SOC) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 280 | 2025-09-01 | 2025-09-18 |
| A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis Stapokibatrt - Atopic Dermatitis | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 240 | 2025-09-01 | 2025-08-06 |
| Study of CM313 in Subject With IgA Nephropathy CM313, Placebo - IgA Nephropathy | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 106 | 2025-09-01 | 2025-09-19 |
| Study of CM559 in Healthy Subjects Placebo, CM559 - Healthy Subjects | Phase 1 | Recruiting | Keymed Biosciences Co.Ltd | 40 | 2025-09-01 | 2025-09-29 |
| Study of CM512 Injection in Subjects With Moderate-to-severe Asthma CM512 injection, Placebo - Asthma | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 200 | 2025-08-19 | 2025-08-28 |
| Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis CM336 Injection(Low dose group), CM336 Injection(High dose group) - Primary Light-Chain Amyloidosis | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 90 | 2025-07-25 | 2025-11-26 |
| Study of CM518D1 in Patients With Advanced Solid Tumors CM518D1 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 434 | 2025-06-27 | 2026-06-15 |
| A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease CM512, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 204 | 2025-06-20 | 2025-05-20 |
| Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis Placebo Comparator, CM512 - Atopic Dermatitis | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 200 | 2025-06-19 | 2025-08-17 |
| Study of Stapokibatrt in Children Subjects With Atopic Dermatitis Stapokibatrt, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 240 | 2025-05-01 | 2025-05-04 |
| Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness CM313(SC) injection-low dose, CM313(SC) injection-high dose - Platelet Transfusion Refractoriness | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 110 | 2025-03-25 | 2025-08-15 |
Showing 20 of 69. Sign in to see all of them.
Dermatitis, Atopic (15) · Asthma (4) · Multiple Myeloma (4) · Rhinitis, Allergic (3) · Alzheimer Disease (2) · Glomerulonephritis, IGA (2) · Lupus Erythematosus, Systemic (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Anemia, Aplastic (1) · Anemia, Hemolytic, Autoimmune (1) · Chronic Urticaria (1) · Disease (1) · Evans Syndrome (1) · Immunoglobulin Light-chain Amyloidosis (1) · Lymphoma (1)
Amyloid (1) · Dexamethasone (1) · Injections (1) · Lenalidomide (1) · Population Groups (1) · Standard of Care (1)
China (64)
Luo Zhang (9) · Jie Hou (3) · Gang An (2) · Hong Wang (2) · Jianzhong Zhang (2) · Jicheng Lv (2) · Jun Shi (2) · Lin Ma (2) · Ruihua Xu (2) · Bo Jiang (1) · Hongmei Jing (1) · Jia Fan (1) · Jian Li (1) · Jinfu Xu (1)
PMID 40185989, PMID 38833140, PMID 37483544, PMID 38299639, PMID 38356731, PMID 38482462, PMID 39080181, PMID 39220573, PMID 39788133, PMID 40051426, PMID 40186079, PMID 40307410, PMID 40650707, PMID 40824573, PMID 40965985, PMID 41022848, PMID 41257453, PMID 41284735, PMID 41290616, PMID 41697953, PMID 42292382